KRTL Holding Highlights SIGMA’s 50-Year Legacy of Innovation, Quality, and Community Leadership in Bolivia

KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company") is pleased to recognize and celebrate the legacy of Industria Químico-Farmacéutica SIGMA Corp SRL ("SIGMA"), its Bolivian partner and a cornerstone of the Latin American pharmaceutical landscape for nearly five decades.

Founded in 1976, SIGMA has established itself as a national leader in the research, manufacturing, and distribution of pharmaceutical, nutraceutical, and biosafety products. With more than 50 years of experience and a reputation built on GMP-certified quality and social responsibility, SIGMA continues to play a critical role in strengthening Bolivia's healthcare infrastructure while expanding its reach into international markets.

"SIGMA is more than a manufacturer—it is a pillar of health and innovation in Bolivia," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Their legacy of compliance, quality, and public impact aligns with KRTL Biotech’s mission to advance science-based solutions for global health."

Origins, Legacy, and Modern Infrastructure

SIGMA’s roots trace back to its early leadership in pharmaceutical distribution through Wilstermann y CIA LTDA, a company that served as the exclusive Bolivian representative for major U.S. and European pharmaceutical brands including UCB Labs (Belgium), William H. Rorer Inc. (USA), Mepha Labs, Medinova Labs (Switzerland), Siegfried Labs (Netherlands), POEN Labs (Argentina), and Saval Labs (Chile). This foundation established SIGMA as a key gateway for innovation in Bolivia’s pharmaceutical market—introducing groundbreaking products such as Zyrtec, Maalox, Camalox, Ananase, Nootropil, Trabit, and B-Alert.

In 1996, the company entered a new era when it was acquired by the board members of Wilstermann y CIA LTDA,  that allowed to expand operations into manufacturing and importation. Notably, SIGMA began producing and distributing select products for Johnson & Johnson, such as Biafine.

Today, operating out of a modern 15,000 m² facility in the Santivañez Industrial Park in Cochabamba, SIGMA's production plant is equipped with European-standard technology and adheres to both national and international regulatory standards. This robust infrastructure supports the company’s diverse product portfolio, which spans essential pharmaceuticals, targeted nutraceuticals, and specialized biosafety solutions.

With active distribution across eight regional hubs in Bolivia—including La Paz, Santa Cruz, Sucre, and Tarija—SIGMA maintains a high level of nationwide reach and reliability in product delivery.

Expanding Product Lines and Contract Manufacturing

SIGMA continues to innovate by expanding its operations into new sectors such as cosmetics and veterinary products, while maintaining its core focus on therapeutics. The company also provides contract manufacturing services to third parties, supporting pharmaceutical and veterinary development under stringent quality control.

"Our mission has always been to evolve with the needs of our communities while maintaining the highest standards of quality and integrity," said Patricia Wilstermann, CEO of SIGMA. "We take pride in producing medicines and nutraceuticals that improve lives, and in opening our platform to collaborators that share our vision."

Social Impact and Strategic Partnerships

SIGMA’s legacy is deeply tied to its commitment to community well-being. From its collaboration with UNICEF during the 2025 Telethon to pandemic-era donations of biosafety supplies and food, the company has long embraced social responsibility as a core value.

Now operating as a unified force under KRTL Biotech, the combined organization is advancing international initiatives to expand access to natural health products and wellness solutions. Future partnerships will focus on integrating organic and functional ingredients with pharmaceutical-grade manufacturing, creating new opportunities for innovation, export readiness, and public health impact across multiple regions.

Through its strategic alignment with KRTL Biotech, SIGMA has also achieved U.S. FDA registration, opening pathways to introduce select formulations into the North American market.

Looking Forward

As SIGMA continues to grow beyond Bolivia’s borders, it remains firmly rooted in its founding principles: quality, transparency, and trust. The company’s decades-long record of manufacturing excellence and commitment to innovation reflect its potential as a key contributor to KRTL’s global platform.

About KRTL Holding Group, Inc.

KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.

About KRTL Biotech, Inc.

KRTL Biotech, Inc. focuses on building scalable life-science operations that prioritize quality, compliance, and innovation. The company aims to expand its international footprint while maintaining rigorous U.S. reporting and regulatory standards.

About Industria Químico Farmacéutica Sigma Corp. S.R.L.

SIGMA is a Bolivian pharmaceutical manufacturer with a long-standing history of quality production, regulatory compliance, and supply chain reliability. The company serves domestic and regional markets through its well-established operations.

For more information:

www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. These risks and uncertainties include, but are not limited to, changes in regulatory requirements, market conditions, and other factors described in the Company’s filings. Additional information concerning risks and uncertainties that could materially affect KRTL’s business and financial results is included in the Company’s filings with the OTC Markets and, where applicable, the SEC. You should not place undue reliance on forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.